TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese patients with type 2 diabetes with a body mass index (BMI)≥18.5 kilograms per square meter (kg/m\^2) but \<40.0 kg/m\^2.~* Patients who are oral antidiabetic drug (OAD) naïve or are taking OAD monotherapy except for a dipeptidyl peptidase-4 inhibitor (DPP-IV) and are willing to discontinue their OAD.~* Patients who are OAD naïve with screening glycosylated hemoglobin (HbA1c) value of 7.0% to 9.5% and randomization HbA1c value of 7.0% to 9.5%, or who are taking OAD monotherapy with screening HbA1c value of 6.0% to 8.5% and randomization HbA1c value of 7.0% to 9.5%.~* Patients who have, in the opinion of the investigator, a stable weight during the 12 weeks prior to screening.~Exclusion Criteria:~* Patients who are currently taking prescription medications to promote weight loss~* Patients who are receiving chronic systemic glucocorticoid therapy, or have received such therapy within 4 weeks immediately prior to screening.~* Patients who have a known clinically significant gastrointestinal disorder, have undergone excision of all or any part of the gastrointestinal tract, have undergone gastric bypass surgery for treatment of obesity, or chronically take drugs that directly influence gastrointestinal motility.~* Patients who have poorly controlled hypertension, renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension.~* Patients who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis. Patients who have amylase and/or lipase of 1.5 times or more the upper limit of the reference range.~* Have a family history, obvious clinical signs, or symptoms of medullary carcinoma of thyroid.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.75 mg LY2189265 (Type: EXPERIMENTAL): None
- 0.5 mg LY2189265 (Type: EXPERIMENTAL): None
- 0.25 mg LY2189265 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women 45-60 years of age;~* post-menopausal;~* ambulatory.~Exclusion Criteria:~* vertebral fracture (except traumatic fracture such as in a motor vehicle accident);~* low-trauma osteoporotic fracture in any other bone;~* breast cancer diagnosed within last 20 years;~* other malignancy diagnosed within last 10 years, except successfully resected basal cell cancer;~* treatment with any bisphosphonate within last 2 years;~* treatment with other drugs affecting bone metabolism within last 6 months.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is female at least 18 years of age~* Subject is able and willing to complete all procedures and follow-up visits indicated in this protocol~* Subject has confirmed stress urinary incontinence (SUI) through cough stress test or urodynamics~* The subject has failed two non-invasive incontinence therapies (such as Kegel exercise, behavior modification, pad use, biofeedback, etc) for \>6 months~Exclusion Criteria:~* Subject has an active urogenital infection or active skin infection in region of surgery~* Subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as determined by POP-Q prolapse grading~* Subject is having a concomitant pelvic floor procedure~* Subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions)~* Subject had a prior surgical SUI treatment~* Subject has undergone radiation or brachy therapy to treat pelvic cancer~* Subject has urge predominant incontinence~* Subject has an atonic bladder or a post void residual (PVR) consistently about 100cc~* Subject is pregnant and/or is planning to get pregnant in the future~* Subject has a contraindication to the surgical procedure or the Altis Instructions For Use (IFU)~* Subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function without the sponsor's approval

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Altis® SIS (Type: OTHER): Subjects enrolled with Altis® SIS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* women 55-80 years of age;~* post-menopausal for \>= 5 years;~* ambulatory.~Exclusion Criteria:~* malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);~* breast cancer within the previous 20 years;~* allergy to bisphosphonates;~* previous treatment with an intravenous bisphosphonate at any time;~* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within the last year, or \>3 months of treatment within the last 2 years.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate 2.5 mg (Type: ACTIVE_COMPARATOR): Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
- Ibandronate 50/50 mg (Type: EXPERIMENTAL): Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
- Ibandronate 100 mg (Type: EXPERIMENTAL): Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
- Ibandronate 150 mg (Type: EXPERIMENTAL): Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HCV+ patients with cryoglobulinemia Vasculitis~2. resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors).~3. Vasculitis is defined according to international criteria: chronic HCV infection (HCV RNA+),~4. serum cryoglobulin superior or equal to 0.05g/l in at least two determinations,~5. presence of the triad purpura-arthralgia-asthenia and/or biopsy proven Vasculitis (kidney, nerve or skin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): it is a single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~Exclusion Criteria:~* Any significant acute or chronic medical illness~* Any history or evidence of abnormal bleeding or coagulation disorders, intracranial hemorrhage, or abnormal bleeding (including heavy menstrual bleeding that has resulted in anemia within the past 1 year) or coagulation disorders in a first degree relative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm A-Apixaban (Type: EXPERIMENTAL): Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
- Arm B-Apixaban (Type: EXPERIMENTAL): Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
- Arm C-Apixaban (Type: EXPERIMENTAL): Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant completed the Wyeth-sponsored PCV13 infant trial study (6096A1-007) at one of the study sites participating in this follow-on study.~2. Aged 39-46 months (inclusive) at time of enrolment.~3. Available for entire study period and whose parent/legal guardian can be reached by telephone.~4. Healthy children as determined by medical history, physical examination, done by a study nurse (and/or study doctor if required, depending on the medical history of the participant and physical assessment), and judgment of the investigator.~5. Parent/legal guardian must be able to complete all relevant study procedures during study participation.~Exclusion Criteria:~1. Has received further doses of pneumococcal vaccination with licensed or investigational pneumococcal vaccine other than those given as part of the Wyeth-sponsored PCV13 infant trial study (6096A1-007).~2. A previous anaphylactic reaction to any vaccine or vaccine-related component.~3. Contraindication to vaccination with pneumococcal conjugate vaccine.~4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~5. Known or suspected immune deficiency or suppression.~6. History of culture-proven invasive disease caused by S pneumoniae.~7. Major known congenital malformation or serious chronic disorder.~8. Significant neurologic disorder or history of seizures including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorder.~9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, synagisB).~10. Participation in another investigational study other than the Wyeth-sponsored PCV13 infant trial study (6096A1-007). Participation in purely observational studies is acceptable.~11. Child who is a direct descendant (child, grandchild) of the study site personnel.

- Gender: ALL
- Minimum Age: 39 Months
- Maximum Age: 46 Months
- Healthy Volunteers: t

Study Arms:
- PCV13 (Type: EXPERIMENTAL): Initial vaccination with PCV13
- PCV7 (Type: EXPERIMENTAL): Initial intervention with PCV7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Combined With Lidocaine Infusion Affect PONV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical statusⅠand Ⅱ~* Aged 40-60 years~* Scheduled for elective laparoscopic hysterectomy~Exclusion Criteria:~* History of allergy to local anesthetics~* BMI\>30~* Severe respiratory disease~* Renal or hepatic insufficiency~* History of preoperative opioids medication and psychiatric~* preoperative bradycardia~* preoperative atrioventricular block~* Subjects who experienced severe hypotension (mean arterial pressure \[MAP\] \<60 mmHg) or bradycardia (heart rate \[HR\] \<40 bpm), urticaria, or arrhythmia during lidocaine and dexmedetomidine infusion period

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Dexmedetomidine Combined With Lidocaine Infusion Affect PONV (Type: EXPERIMENTAL): None
- Effect of infusion saline on PONV (Type: EXPERIMENTAL): None
- Effect of infusion lidocaine on PONV (Type: EXPERIMENTAL): None
- Effect of infusion dexmedetomidine on PONV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index must be between 17 kg/m\^2 and ≤ 33 kg/m\^2;~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use appropriate contraception;~* Males agree to use appropriate contraception;~* Diagnosis of TTR amyloidosis;~* Adequate blood counts, liver and renal function;~* Willing to give written informed consent and are willing to comply with the study requirements.~Exclusion Criteria:~* Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;~* Received an investigational agent, other than tafamidis or diflunisal, within 30 days prior to first dose study drug administration;~* Prior liver transplant;~* Poor cardiac function;~* Considered unfit for the study by the Principal Investigator;~* Employee or family member of the sponsor or the clinical study site personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patisiran (ALN-TTR02) (Type: EXPERIMENTAL): Two administrations of patisiran will be administered once every 4 weeks \[Q4W\]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks \[Q3W\]), and an alternative premedication regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of active or inactive non-infectious uveitis (pan, anterior, intermediate and posterior)~* ETDRS BCVA score of ≥ 5 letters read in the study eye~Exclusion Criteria:~* Any active ocular disease or infection in the study eye other than uveitis~* Intraocular pressure \> 22 mmHg or uncontrolled glaucoma in the study eye; patients with IOP of 22 or less in the study eye not excluded with no more than 2 IOP-lowering medications.~* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study~* Any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an OZURDEX implant in the 6 months prior to baseline; RETISERT or ILUVIEN implant in the 3 years prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg CLS-TA Suprachoriodal Injection (Type: EXPERIMENTAL): Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years and older.~* Overactive bladder symptoms for greater than or equal to 3 months and as documented in a 3-day patient diary following screening and preceding baseline visit: \> 1 urge episodes/24 hours (average); greater than or equal to 8 micturitions/24 hours (average)~Exclusion Criteria:~* Urinary tract infection, chronic inflammation such as interstitial cystitis and bladder stones~* Clinically significant outflow obstruction~* Uncontrolled narrow angle glaucoma, urinary, or gastric retention~* Severe renal or hepatic impairment~* Chronic severe constipation or history of diagnosed GI obstructive disease~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Diagnosis or history of neurogenic bladder~* History of bladder or pelvic cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solifenacin (Type: EXPERIMENTAL): Solifenacin succinate: 5 mg tablets, taken orally, once daily
- Oxybutynin IR (Type: ACTIVE_COMPARATOR): Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Conductive hearing loss in the implanted ear. Bone conduction thresholds with a pure tone average of 500, 1000, 2000 and 3000 Hz \<30 decibel (dB) hearing level (HL)~* Single-sided Sensorineural Deafness (SSD). Bone conduction thresholds with a pure tone average of 500, 1000, 2000 and 3000 Hz \<30 dB hearing level (HL) in the best ear~* Signed informed consent~Exclusion Criteria:~* Uncontrolled diabetes as judged by the investigator~* Condition that could jeopardize osseointegration and/or wound healing, e.g. osteoporosis, psoriasis and use of corticosteroids~* Unable to follow investigational procedures, e.g. to complete quality of life scales~* Less than 4mm of soft tissue pre-operatively~* Participation in another investigation with pharmaceuticals and/or device~* Condition that may have an impact on the outcome of the investigation as judged by the investigator~* Subjects that have received radiation therapy at the same side of the skull where the Baha Attract will be positioned~* Suitable implant position for the Baha BI300 implant system (4 mm and 3 mm) not found during surgery due to insufficient bone quality and/or bone thickness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baha Attract System (Type: EXPERIMENTAL): This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~* One implant magnet~* One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete